Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06983028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atacicept in Multiple Glomerular Diseases

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 200 → 250 participants Eligibility criteria expanded, about 72 words · Study description shortened, about 7 wordsv4 Show 2 more changesShow less
    • Eligibility criteria expanded, about 72 words
    • Study description shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 3 wordsv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of May 2025 to Jul 7, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2025 to Jul 7, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Trial Details
NCT Number NCT06983028
Lead Sponsor Vera Therapeutics, Inc.
Conditions pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov